DENEX, Renal Denervation Therapy, in Patients With Hypertension on no or 1-3 Antihypertensive Medications

Inclusion Criteria: * Subject aged 19 to 75 years old * Subject should maintain the 0 to 3 antihypertensive medications of different classes, ACE-I, ARB, beta blocker, CCB or diuretics, without change for at least 4 weeks of run-in period between primary screening and secondary screening and for at least 3 months after the procedure * Subject with 140 mmHg ≤ average office SBP \< 180 mmHg and 90 mmHg ≤ office DBP \< 120 mmHg at primary and secondary screening * Subject with 135 mmHg ≤ average daytime ambulatory SBP \<170 mmHg and 85 mmHg ≤ average daytime ambulatory DBP \< 105 mmHg at secondary screening after the run-in period for at least 4 weeks Exclusion Criteria: * Subject with the anatomical findings in kidney or renal artery which preclude renal denervation * Subject with type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus * Subject with eGFR less than 40mL/min/1.73㎡ * Subject with a brachial circumference greater than 42 cm. * Subject with secondary hypertension (except for sleep apnea patients) * Subject with a medical history of cerebrovascular disease or severe cardiovascular disease within 12 months prior to obtaining the consent or patients newly diagnosed with such diseases before enrollment. * Subject rehospitalized two or more times for hypertensive crisis within 12 months prior to obtaining consent or hospitalized for hypertensive crisis within three months prior to obtaining consent. * Subject with chronic oxygen therapy or mechanical ventilation (except for sleep apnea) * Subject with primary pulmonary hypertension